Company intelligence
benfovir AG
Biotechnology Research
Darmstadt, DE
7 employees
Founded 2020
3 public signals
About benfovir AG
benfovir AG is a pharmaceutical company based in Darmstadt in Hesse that specializes in the therapy of viral infections such as the SARS-CoV-2 virus. At this stage, one compound is under clinical development. This compound inhibits the sugar metabolism in infected cells by disabling the formation of the crucial building blocks for virus production (ribose-5-phosphate and acetyl-CoA), and at the same time by preventing the overshooting of the immune system.
Verified activity
Signals from benfovir AG
3 published signals
Research & Knowledge
benfovir AG published a study in Science showing that tumors release the antioxidant enzyme PRDX1 into their surroundings to weaken T-cell activation and antitumor activity.
Reported by Natasja de Bruin
Presence & Recognition
benfovir AG is hosting the NCL Group's 54th anniversary celebration in Paderborn, starting on September 3, 2026, with a focus on discussions and a DJ event.
Reported by Kathrin Riepe
Presence & Recognition
benfovir AG participated in the House of Pharma & Healthcare 15th anniversary conference
Reported by Kathrin Riepe